Bristol Myers Squibb announced plans for a new manufacturing plant in Devens, Mass., adding to the company’s cell therapy network.
A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
Texas-based Molecular Templates (MTEM) and Bristol Myers Squibb forged a strategic research collaboration worth a potential $1.3 billion to discover and develop multiple oncology therapies using a next-generation engineered toxin body platform.
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
B-cell maturation antigen (BCMA), Biologics License Application (BLA), Bristol Myers Squibb, Business, CAR-T Therapy, Clinical Trials, PDUFA, R&D, Relapsed Or Refractory (R/R) Large B-Cell Lymphoma (LBCL), Therapeutics, Write-offsBristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.
The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).
FDA Approves Opdivo-Cabometyx Combo for Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma (RCC), Approvals, Blockbusters, Bristol Myers Squibb, Clinical Trials, Combination Therapies, FDA, First-Line Treatment, Metastatic Renal Cell Carcinoma (mRCC), R&D, Real-Time Oncology Review (RTOR) Pilot, TherapeuticsBristol Myers Squibb’s Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration for the first-line treatment of patients with advanced renal cell carcinoma.
ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope
Acute Myeloid Leukemia (AML), American Society of Hematology (ASH) Annual Meeting, Analysts, Bristol Myers Squibb, Business, CAR-T Therapy, CD47 Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Clinical Trials, CRISPR, Data, Gene Therapy, Janssen, Johnson & Johnson, Large B-Cell Lymphoma, Monoclonal Antibodies, New England Journal of Medicine, R&D, Sickle Cell Disease, Therapeutics, Transfusion-Dependent Beta-Thalassemia (TDT)The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.
FDA delays decision on Bristol Myers cancer therapy due to Covid-19 travel curbs
Acquisitions, Biologics License Application (BLA), Blood Cancers, Bristol Myers Squibb, Business, Coronavirus Restrictions, Facilities/Sites/Manufacturing, FDA, Investors, R&D, Relapsed Or Refractory (R/R) Large B-Cell Lymphoma (LBCL), TexasBristol Myers Squibb said the U.S. health regulator deferred a decision on an experimental blood cancer therapy that the company acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.